Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development

6 Jul 2022

Abstract excerpt

Glioblastoma multiform is the most aggressive primary type of brain tumor, representing 54% of all gliomas. The average life span for glioblastoma multiform is around 14-15 months instead of treatment. The current treatment for glioblastoma multiform includes surgical removal of the tumor followed by radiation therapy and temozolomide chemotherapy for 6.5 months, followed by another 6 months of maintenance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Glioma Diagnosis and Treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35873570
DOI: 10.3389/fphar.2022.939570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical DevelopmentPMID 35873570Read ↗

PARP Inhibitors in Glioma: A Review of Therapeutic OpportunitiesSemantic proximity Read ↗

Therapeutic Application of PARP Inhibitors in Neuro-Oncology.Semantic proximity Read ↗

Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP InhibitorsSemantic proximity Read ↗

Olaparib: A Chemosensitizer for the Treatment of GlioblastomaSemantic proximity Read ↗

PARP Inhibitor Counteracts Temozolomide Resistance in Glioblastoma MultiformeSemantic proximity Read ↗

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read ↗

The Study on the Expression Level of PARP-1 in Glioma and Computational Screening of PARP-1 InhibitorsSemantic proximity Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?Semantic proximity Read ↗

BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma MultiformeSemantic proximity Read ↗

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.Semantic proximity Read ↗

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future DirectionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.